Centessa Pharmaceuticals plc (CNTA)

8,89 0,00 (0,00%) Al cierre: 04:00PM EDT

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom

https://www.centessa.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 77

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Saurabh Saha M.D., Ph.D.	CEO & Director	1,04M	N/A	1976
Dr. David M. Chao Ph.D.	Chief Administrative Officer	710,3k	N/A	1968
Dr. Antoine Yver M.D., M.Sc.	Executive VP & Chairman of Development	773,14k	N/A	1958
Dr. Gregory M. Weinhoff M.B.A., M.D.	Chief Business Officer	655k	N/A	1971
Ms. Tia L. Bush	Chief Technology & Quality Officer	N/A	N/A	1971
Ms. Kristen K. Sheppard Esq., J.D.	Senior Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Iqbal J. Hussain L.L.B.	General Counsel, Chief Compliance Officer & Corporate Secretary	N/A	N/A	1981
Ms. Karen M. Anderson	Chief People Officer	N/A	N/A	1968
Dr. Mario Alberto Accardi Ph.D.	President of the Orexin Program	N/A	N/A	N/A
Dr. Harris L. Rotman Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de Centessa Pharmaceuticals plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.